Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

September 23, 2019

Study Completion Date

September 23, 2019

Conditions
Lung Cancer
Interventions
DRUG

Minocycline

100 mg by mouth two times a day (200 mg/day) every day for 7 weeks, starting on the first week of chemoradiation therapy.

OTHER

Placebo

1 capsule by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy.

BEHAVIORAL

Questionnaires

Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01636934 - Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy | Biotech Hunter | Biotech Hunter